Werewolf Therapeutics Stock Short Ratio
| HOWL Stock | USD 1.31 0.09 6.43% |
Fundamental analysis of Werewolf Therapeutics allows traders to better anticipate movements in Werewolf Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Werewolf | Short Ratio | Build AI portfolio with Werewolf Stock |
Werewolf Therapeutics Company Short Ratio Analysis
Werewolf Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Werewolf Therapeutics Short Ratio | 0.55 X |
Most of Werewolf Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Werewolf Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Werewolf Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Werewolf Therapeutics is extremely important. It helps to project a fair market value of Werewolf Stock properly, considering its historical fundamentals such as Short Ratio. Since Werewolf Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Werewolf Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Werewolf Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Werewolf Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Werewolf Therapeutics has a Short Ratio of 0.55 times. This is 85.9% lower than that of the Biotechnology sector and 92.58% lower than that of the Health Care industry. The short ratio for all United States stocks is 86.25% higher than that of the company.
Werewolf Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Werewolf Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics of similar companies.Werewolf Therapeutics is currently under evaluation in short ratio category among its peers.
Werewolf Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Werewolf Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Werewolf Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Werewolf Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 328 K | Renaissance Technologies Corp | 2025-06-30 | 316.3 K | Alyeska Investment Group, L.p. | 2025-06-30 | 235.7 K | Goldman Sachs Group Inc | 2025-06-30 | 227.4 K | State Street Corp | 2025-06-30 | 119.2 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 103.8 K | Bridgeway Capital Management, Llc | 2025-06-30 | 102 K | Aqr Capital Management Llc | 2025-06-30 | 92.2 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 84.4 K | Ra Capital Management, Llc | 2025-06-30 | 6.7 M | Mpm Asset Management, Llc | 2025-06-30 | 4.3 M |
Werewolf Fundamentals
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 47.35 M | ||||
| Shares Outstanding | 45.73 M | ||||
| Shares Owned By Insiders | 5.95 % | ||||
| Shares Owned By Institutions | 49.12 % | ||||
| Number Of Shares Shorted | 824.14 K | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 52.22 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (52.42 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 37.09 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 6.83 | ||||
| Number Of Employees | 46 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 64.02 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
| Net Asset | 126.93 M |
About Werewolf Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Werewolf Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Werewolf Therapeutics Piotroski F Score and Werewolf Therapeutics Altman Z Score analysis. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.